A Phase 2b/3, Adaptive, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Danicamtiv in Participants with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-DCM).
Фаза 3 – широко изпитване преди одобрение
Заболявания:
Symptomatic genetic and familial dilated cardiomyopathy.
Спонсор: Kardigan Inc.
Налично на:
БГ
Обобщение
Trial status: Authorised
Change from Baseline (Day 1) to Week 26 in left atrial function index (LAFI) in Cohort 1., Change from Baseline (Day 1) to Week 26 in peak oxygen consumption (pVO2) in Cohort 1.
Кой може да участва
Age group: 65+ years, 18-64 years
Gender: Female, Male
Target enrollment: 178 participants
Интервенции
Danicamtiv
Drug
Placebo tablets contain the same excipients as Danicamtiv tablets except the active substance.
БГ
EN